1871.5000 1.50 (0.08%)
NSE Nov 18, 2026 15:31 PM
Volume: 1.7M
 

1871.50
0.08%
Emkay
Sun’s Organon acquisition marks a clear departure from its recent acquisition template – multiple sub-USD500mn assets over the years vs adding a company of its own scale as part of a single acquisition.
Promoters unpledged 1.64% of shares in last quarter. Total pledge stands at 0.01% of promoter holdings
More from Sun Pharmaceutical Industries Ltd.
Recommended